1. SiegelR, NaishadhamD, JemalA. Cancer statistics, 2013. CA Cancer J Clin2013;63:11. CrossRef

2. HowladerNA, KrapchoM, NeymanN, et al.(eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD; 2011.

3. LiD, MorrisJS, LiuJ, et al.Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA2009;301:2553. CrossRef

4. ArslanAA, HelzlsouerKJ, KooperbergC, et al.Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med2010;170:791. CrossRef

5. Berrington de GonzalezA, SweetlandS, SpencerE. A meta‐analysis of obesity and the risk of pancreatic cancer. Br J Cancer2003;89:519. CrossRef

6. JiaoL, Berrington de GonzalezA, HartgeP, et al.Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control2010;21:1305. CrossRef

7. LarssonSC, OrsiniN, WolkA. Body mass index and pancreatic cancer risk: a meta‐analysis of prospective studies. Int J Cancer2007;120:1993. CrossRef

8. RenehanAG, TysonM, EggerM, et al.Body‐mass index and incidence of cancer: a systematic review and meta‐analysis of prospective observational studies. Lancet2008;371:569. CrossRef

9. FuchsCS, ColditzGA, StampferMJ, et al.A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med1996;156:2255. CrossRef

10. IodiceS, GandiniS, MaisonneuveP, et al.Tobacco and the risk of pancreatic cancer: a review and meta‐analysis. Langenbecks Arch Surg2008;393:535. CrossRef

11. GandiniS, BotteriE, IodiceS, et al.Tobacco smoking and cancer: a meta‐analysis. Int J Cancer2008;122:155. CrossRef

12. HenleySJ, ThunMJ, ChaoA, et al.Association between exclusive pipe smoking and mortality from cancer and other diseases. J Natl Cancer Inst2004;96:853. CrossRef

13. BoffettaP, AagnesB, WeiderpassE, et al.Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer2005;114:992. CrossRef

14. ZhouJ, WelleniusGA, MichaudDS. Environmental tobacco smoke and the risk of pancreatic cancer among non‐smokers: a meta‐analysis. Occup Environ Med2012;69:853. CrossRef

15. VrielingA, Bueno‐de‐MesquitaHB, BoshuizenHC, et al.Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer2010;126:2394.

16. ElenaJW, SteplowskiE, YuK, et al.Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control2013;24:13. CrossRef

17. HuxleyR, Ansary‐MoghaddamA, Berrington de GonzalezA, et al.Type‐II diabetes and pancreatic cancer: a meta‐analysis of 36 studies. Br J Cancer2005;92:2076. CrossRef

18. EverhartJ, WrightD. Diabetes mellitus as a risk factor for pancreatic cancer. A meta‐analysis. JAMA1995;273:1605. CrossRef

19. OnitiloAA, EngelJM, GlurichI, et al.Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control2012;23:967. CrossRef

20. BowkerSL, MajumdarSR, VeugelersP, et al.Increased cancer‐related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care2006;29:254. CrossRef

21. EvansJM, DonnellyLA, Emslie‐SmithAM, et al.Metformin and reduced risk of cancer in diabetic patients. BMJ2005;330:1304. CrossRef

22. SinghS, SinghPP, SinghAG, et al.Anti‐diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta‐analysis. Am J Gastroenterol2013;108:510; quiz 20. CrossRef

23. LiD, YeungSC, HassanMM, et al.Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology2009;137:482. CrossRef

24. ZhangP, LiH, TanX, et al.Association of metformin use with cancer incidence and mortality: a meta‐analysis. Cancer Epidemiol2013;37:207. CrossRef

25. SadeghiN, AbbruzzeseJL, YeungSC, et al.Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res2012;18:2905. CrossRef

26. EngelSS, Williams‐HermanDE, GolmGT, et al.Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract2010;64:984. CrossRef

27. ScheenA. Gliptins (dipeptidyl peptidase‐4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf2013;12:545. CrossRef

28. ElashoffM, MatveyenkoAV, GierB, et al.Pancreatitis, pancreatic, and thyroid cancer with glucagon‐like peptide‐1‐based therapies. Gastroenterology2011;141:150. CrossRef

29. GierB, MatveyenkoAV, KirakossianD, et al.1 receptor activation by exendin‐4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes2012;61:1250. CrossRef

30. DoreDD, SeegerJD, Arnold ChanK. Use of a claims‐based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin2009;25:1019. CrossRef

31. DruckerDJ, ShermanSI, BergenstalRM, et al.The safety of incretin‐based therapies – review of the scientific evidence. J Clin Endocrinol Metab2011;96:2027. CrossRef

32. SchneiderA, SingerMV. Alcoholic pancreatitis. Dig Dis2005;23:222. CrossRef

33. VelemaJP, WalkerAM, GoldEB. Alcohol and pancreatic cancer. Insufficient epidemiologic evidence for a causal relationship. Epidemiol Rev1986;8:28.

34. FriedmanGD, van den EedenSK. Risk factors for pancreatic cancer: an exploratory study. Int J Epidemiol1993;22:30. CrossRef

35. JiaoL, SilvermanDT, SchairerC, et al.Alcohol use and risk of pancreatic cancer: the NIH‐AARP Diet and Health Study. Am J Epidemiol2009;169:1043. CrossRef

36. RaimondiS, LowenfelsAB, Morselli‐LabateAM, et al.Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol2010;24:349. CrossRef

37. LowenfelsAB, MaisonneuveP, CavalliniG, et al.Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med1993;328:1433. CrossRef

38. TalaminiG, FalconiM, BassiC, et al.Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol1999;94:1253. CrossRef

39. JiaoL, MitrouPN, ReedyJ, et al.A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med2009;169:764. CrossRef

40. Stolzenberg‐SolomonRZ, CrossAJ, SilvermanDT, et al.Meat and meat‐mutagen intake and pancreatic cancer risk in the NIH‐AARP cohort. Cancer Epidemiol Biomarkers Prev2007;16:2664. CrossRef

41. VrielingA, VerhageBA, van DuijnhovenFJ, et al.Fruit and vegetable consumption and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer2009;124:1926. CrossRef

42. JansenRJ, RobinsonDP, Stolzenberg‐SolomonRZ, et al.Nutrients from fruit and vegetable consumption reduce the risk of pancreatic cancer. J Gastrointest Cancer2013;44:152. CrossRef

43. YadavD, LowenfelsAB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology2013;144:1252. CrossRef

44. KleinAP, HrubanRH, BruneKA, et al.Familial pancreatic cancer. Cancer J2001;7:266.

45. JacobsEJ, ChanockSJ, FuchsCS, et al.Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer2010;127:1421. CrossRef

46. GhadirianP, BoyleP, SimardA, et al.Reported family aggregation of pancreatic cancer within a population‐based case‐control study in the Francophone community in Montreal, Canada. Int J Pancreatol1991;10:183.

47. SolomonS, DasS, BrandR, et al.Inherited pancreatic cancer syndromes. Cancer J2012;18:485. CrossRef

48. BartschDK, GressTM, LangerP. Familial pancreatic cancer – current knowledge. Nat Rev Gastroenterol Hepatol2012;9:445. CrossRef

49. LangerP, SlaterE, FendrichV, et al.Familial pancreatic cancer: current status. Expert Opin Med Diagn2007;1:193. CrossRef

50. ShiC, HrubanRH, KleinAP. Familial pancreatic cancer. Arch Pathol Lab Med2009;133:365.

51. McCarthyDM, BratDJ, WilentzRE, et al.Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. Hum Pathol2001;32:638. CrossRef

52. HrubanRH, AdsayNV, Albores‐SaavedraJ, et al.Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol2001;25:579. CrossRef

53. WilentzRE, HrubanRH. Pathology of cancer of the pancreas. Surg Oncol Clin N Am1998;7:43.

54. ProvenzanoPP, CuevasC, ChangAE, et al.Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell2012;21:418. CrossRef

55. ApteMV, ParkS, PhillipsPA, et al.Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas2004;29:179. CrossRef

56. KloppelGSE, LongneckerDS, CapellaS, et al.Histological Histological Typing of Tumours of the Exocrine Pancreas. World Health Organization International Classification of Tumors. Berlin: Springer; 1996: 11. CrossRef

57. HrubanRHKD, PitmanMB(eds). Tumors of the Pancreas. Atlas of Tumor Pathology, 4th edition. Washington, DC: Armed Forces Institute of Pathology; 2006.

58. KloppelG, LingenthalG, von BulowM, et al.Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico‐histopathological correlation in a series of 75 cases. Histopathology1985;9:841. CrossRef

59. LeeMJ, LeeHS, KimWH, et al.Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol2003;16:403. CrossRef

60. DuvalJV, SavasL, BannerBF. Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med2000;124:1196.

61. GoldsteinNS, BassiD. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut‐point threshold. Am J Clin Pathol2001;115:695. CrossRef

62. MaitraA, FukushimaN, TakaoriK, et al.Precursors to invasive pancreatic cancer. Adv Anat Pathol2005;12:81. CrossRef

63. HingoraniSR, PetricoinEF, MaitraA, et al.Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell2003;4:437. CrossRef

64. AguirreAJ, BardeesyN, SinhaM, et al.Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev2003;17:3112. CrossRef

65. CampbellPJ, YachidaS, MudieLJ, et al.The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature2010;467:1109. CrossRef

66. JonesS, ZhangX, ParsonsDW, et al.Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science2008;321:1801. CrossRef

67. AlmogueraC, ShibataD, ForresterK, et al.Most human carcinomas of the exocrine pancreas contain mutant c‐K‐ras genes. Cell1988;53:549. CrossRef

68. SmitVT, BootAJ, SmitsAM, et al.KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res1988;16:7773. CrossRef

69. CalhounEKS. Molecular genetics of pancreatic cancer. In: LowyAMLS, PhilipPA(eds). Pancreatic Cancer. New York, NY: Springer; 2008: 27. CrossRef

70. KleinAP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer2013;13:66. CrossRef

71. HingoraniSR, WangL, MultaniAS, et al.Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell2005;7:469. CrossRef

72. MortonJP, TimpsonP, KarimSA, et al.Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A2010;107:246. CrossRef

73. WhitcombDC. Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol2004;287:G315. CrossRef

74. BiankinAV, WaddellN, KassahnKS, et al.Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature2012;491:399. CrossRef

75. MiyamotoY, MaitraA, GhoshB, et al.Notch mediates TGF alpha‐induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell2003;3:565. CrossRef

76. ThayerSP, di MaglianoMP, HeiserPW, et al.Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature2003;425:851. CrossRef

77. OliveKP, JacobetzMA, DavidsonCJ, et al.Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science2009;324:1457. CrossRef

78. PlentzR, ParkJS, RhimAD, et al.Inhibition of gamma‐secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology2009;136:1741. CrossRef

79. WellsJM, EsniF, BoivinGP, et al.Wnt/beta‐catenin signaling is required for development of the exocrine pancreas. BMC Dev Biol2007;7:4. CrossRef

80. Pasca di MaglianoM, BiankinAV, HeiserPW, et al.Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS ONE2007;2:e1155. CrossRef

81. ZhangY, MorrisJPt, YanW, et al.Canonical Wnt signaling Is required for pancreatic carcinogenesis. Cancer Res2013;73:4909. CrossRef

82. FeigC, GopinathanA, NeesseA, et al.The pancreas cancer microenvironment. Clin Cancer Res2012;18:4266. CrossRef

83. RuffellB, AffaraNI, CoussensLM. Differential macrophage programming in the tumor microenvironment. Trends Immunol2012;33:119. CrossRef

84. SchmidMC, AvraamidesCJ, DippoldHC, et al.Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell2011;19:715. CrossRef

85. JacobetzMA, ChanDS, NeesseA, et al.Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut2013;62:112. CrossRef

86. LiC, HeidtDG, DalerbaP, et al.Identification of pancreatic cancer stem cells. Cancer Res2007;67:1030. CrossRef

87. PenchevVR, RasheedZA, MaitraA, et al.Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res2012;18:4277. CrossRef

88. Garcia‐SilvaS, Frias‐AldeguerJ, HeeschenC. Stem cells & pancreatic cancer. Pancreatology2013;13:110. CrossRef

89. HermannPC, HuberSL, HerrlerT, et al.Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell2007;1:313. CrossRef

90. HermannPC, MuellerMT, HeeschenC. Pancreatic cancer stem cells – insights and perspectives. Expert Opin Biol Ther2009;9:1271. CrossRef

91. LiC, WuJJ, HynesM, et al.c‐Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology2011;141:2218. CrossRef

92. RhimAD, MirekET, AielloNM, et al.EMT and dissemination precede pancreatic tumor formation. Cell2012;148:349. CrossRef

93. KatzMH, SavidesTJ, MoossaAR, et al.An evidence‐based approach to the diagnosis and staging of pancreatic cancer. Pancreatology2005;5:576. CrossRef

94. ClarkeDL, ThomsonSR, MadibaTE, et al.Preoperative imaging of pancreatic cancer: a management‐oriented approach. J Am Coll Surg2003;196:119. CrossRef

95. FletcherJG, WiersemaMJ, FarrellMA, et al.Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi‐detector row CT. Radiology2003;229:81. CrossRef

96. ImbriacoM, MegibowAJ, CameraL, et al.Dual‐phase versus single‐phase helical CT to detect and assess resectability of pancreatic carcinoma. Am J Roentgenol2002;178:1473. CrossRef

97. BronsteinYL, LoyerEM, KaurH, et al.Detection of small pancreatic tumors with multiphasic helical CT. Am J Roentgenol2004;182:619. CrossRef

98. BipatS, PhoaSS, van DeldenOM, et al.Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta‐analysis. J Comput Assist Tomogr2005;29:438. CrossRef

99. SorianoA, CastellsA, AyusoC, et al.Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol2004;99:492. CrossRef

100. De AngelisC, BrizziRF, PellicanoR. Endoscopic ultrasonography for pancreatic cancer: current and future perspectives. J Gastrointest Oncol2013;4:220.

101. TurnerBG, CizginerS, AgarwalD, et al.Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy. Gastrointest Endosc2010;71:91. CrossRef

102. MunroeCA, FehmiSM, SavidesTJ. Endoscopic ultrasound in the diagnosis of pancreatic cancer. Exp Opin Med Diagn2013;7:25. CrossRef

103. TemperoMA, KlimstraD, BerlinJ, et al.Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res2013;19:538. CrossRef

104. ShahSM, RibeiroA, LeviJ, et al.EUS‐guided fine needle aspiration with and without trucut biopsy of pancreatic masses. JOP2008;9:422.

105. KidaM, ArakiM, MiyazawaS, et al.Comparison of diagnostic accuracy of endoscopic ultrasound‐guided fine‐needle aspiration with 22‐ and 25‐gauge needles in the same patients. J Interv Gastroenterol2011;1:102.

106. TammEP, BhosalePR, VikramR, et al.Imaging of pancreatic ductal adenocarcinoma: state of the art. World J Radiol2013;5:98. CrossRef

107. WinnerM, AllendorfJD, SaifMW. An update on surgical staging of patients with pancreatic cancer. JOP2012;13:143.

108. WarshawAL, TepperJE, ShipleyWU. Laparoscopy in the staging and planning of therapy for pancreatic cancer. Am J Surg1986;151:76. CrossRef

109. MaithelSK, MaloneyS, WinstonC, et al.Preoperative CA 19‐9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol2008;15:3512. CrossRef

110. MinnardEA, ConlonKC, HoosA, et al.Laparoscopic ultrasound enhances standard laparoscopy in the staging of pancreatic cancer. Ann Surg1998;228:182. CrossRef

111. CalleryMP, StrasbergSM, DohertyGM, et al.Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. J Am Coll Surg1997;185:33. CrossRef

112. PovoskiSP, KarpehMSJr, ConlonKC, et al.Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy. Ann Surg1999;230:131. CrossRef

113. SohnTA, YeoCJ, CameronJL, et al.Do preoperative biliary stents increase postpancreaticoduodenectomy complications?J Gastrointest Surg2000;4:258; discussion 67. CrossRef

114. PistersPW, HudecWA, HessKR, et al.Effect of preoperative biliary decompression on pancreaticoduodenectomy‐associated morbidity in 300 consecutive patients. Ann Surg2001;234:47. CrossRef

115. AadamAA, EvansDB, KhanA, et al.Efficacy and safety of self‐expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc2012;76:67. CrossRef

116. CavellLK, AllenPJ, VinoyaC, et al.Biliary self‐expandable metal stents do not adversely affect pancreaticoduodenectomy. Am J Gastroenterol2013;108:1168. CrossRef

117. ChristiansKK, TsaiS, TolatPP, et al.Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. J Surg Oncol2013;107:33. CrossRef

118. TranKT, SmeenkHG, van EijckCH, et al.Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg2004;240:738. CrossRef

119. Di CarloV, ZerbiA, BalzanoG, et al.Pylorus‐preserving pancreaticoduodenectomy versus conventional whipple operation. World J Surg1999;23:920. CrossRef

120. ZerbiA, BalzanoG, PatuzzoR, et al.Comparison between pylorus‐preserving and Whipple pancreatoduodenectomy. Br J Surg1995;82:975. CrossRef

121. LillemoeKD, CameronJL, KimMP, et al.Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg2004;8:766; discussion 72. CrossRef

122. LowyAM, LeeJE, PistersPW, et al.Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg1997;226:632. CrossRef

123. YeoCJ, CameronJL, LillemoeKD, et al.Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo‐controlled trial. Ann Surg2000;232:419. CrossRef

124. ConlonKC, LabowD, LeungD, et al.Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection. Ann Surg2001;234:487; discussion 93. CrossRef

125. van der WiltAA, CoolsenMM, de HinghIH, et al.To drain or not to drain: a cumulative meta‐analysis of the use of routine abdominal drains after pancreatic resection. HPB (Oxford)2013;15:337. CrossRef

126. Van BurenG2nd, BloomstonM, HughesSJ, et al.A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg2014;259:605. CrossRef

127. NimuraY, NaginoM, TakaoS, et al.Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long‐term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci2012;19:230. CrossRef

128. IqbalN, LovegroveRE, TilneyHS, et al.A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: a meta‐analysis of 1909 patients. Eur J Surg Oncol2009;35:79. CrossRef

129. FarnellMB, AranhaGV, NimuraY, et al.The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence. J Gastrointest Surg2008;12:651. CrossRef

130. YeoCJ, CameronJL, SohnTA, et al.Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short‐term outcome. Ann Surg1999;229:613; discussion 22. CrossRef

131. HarrisonLE, KlimstraDS, BrennanMF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?Ann Surg1996;224:342, discussion 7. CrossRef

132. LeachSD, LeeJE, CharnsangavejC, et al.Survival following pancreaticoduodenectomy with resection of the superior mesenteric‐portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg1998;85:611. CrossRef

133. BirkmeyerJD, WarshawAL, FinlaysonSR, et al.Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery1999;126:178. CrossRef

134. SosaJA, BowmanHM, GordonTA, et al.Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg1998;228:429. CrossRef

135. RosemurgyAS, BloomstonM, SerafiniFM, et al.Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in‐hospital mortality. J Gastrointest Surg2001;5:21. CrossRef

136. GoumaDJ, van GeenenRC, van GulikTM, et al.Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg2000;232:786. CrossRef

137. LiebermanMD, KilburnH, LindseyM, et al.Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg1995;222:638. CrossRef

138. KoobyDA, GillespieT, BentremD, et al.Left‐sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg2008;248:438.

139. KalserMH, EllenbergSS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg1985;120:899. CrossRef

140. KlinkenbijlJH, JeekelJ, SahmoudT, et al.Adjuvant radiotherapy and 5‐fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg1999;230:776; discussion 82. CrossRef

141. NeoptolemosJP, StockenDD, FriessH, et al.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med2004;350:1200. CrossRef

142. OettleH, PostS, NeuhausP, et al.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative‐intent resection of pancreatic cancer: a randomized controlled trial. JAMA2007;297:267. CrossRef

143. NeoptolemosJP, StockenDD, BassiC, et al.Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA2010;304:1073. CrossRef

144. RegineWF, WinterKA, AbramsRA, et al.Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil‐based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA2008;299:1019. CrossRef

145. PicozziVJ, AbramsRA, DeckerPA, et al.Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5‐fluorouracil, and interferon‐alfa‐2b‐based chemoradiation: ACOSOG Trial Z05031. Ann Oncol2011;22:348. CrossRef

146. SchmidtJ, AbelU, DebusJ, et al.Open‐label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa‐2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol2012;30:4077. CrossRef

147. EvansDB, RichTA, ByrdDR, et al.Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg1992;127:1335. CrossRef

148. PistersPW, AbbruzzeseJL, JanjanNA, et al.Rapid‐fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol1998;16:3843.

149. PistersPW, WolffRA, JanjanNA, et al.Preoperative paclitaxel and concurrent rapid‐fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event‐free outcome. J Clin Oncol2002;20:2537. CrossRef

150. EvansDB, VaradhacharyGR, CraneCH, et al.Preoperative gemcitabine‐based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol2008;26:3496. CrossRef

151. VaradhacharyGR, WolffRA, CraneCH, et al.Preoperative gemcitabine and cisplatin followed by gemcitabine‐based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol2008;26:3487. CrossRef

152. VaradhacharyGR, TammEP, AbbruzzeseJL, et al.Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol2006;13:1035. CrossRef

153. CalleryMP, ChangKJ, FishmanEK, et al.Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol2009;16:1727. CrossRef

154. KatzMH, PistersPW, EvansDB, et al.Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg2008;206:833; discussion 46. CrossRef

155. KatzMH, FlemingJB, BhosaleP, et al.Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer2012;118:5749. CrossRef

156. RoldanGE, GundersonLL, NagorneyDM, et al.External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer1988;61:1110. CrossRef

157. MoertelCG, AhmannDL, TaylorWF, et al.Aspirin and pancreatic cancer pain. Gastroenterology1971;60:552.

158. CohenSJDRJ, LipsitzS, CatalanoPJ, et al.A randomized phase III study of radiotherapy alone or with 5‐fluorouracil and mitomycin‐C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys2005;62:1345. CrossRef

159. SultanaA, SmithCT, CunninghamD, et al.Meta‐analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol2007;25:2607. CrossRef

160. SultanaA, Tudur SmithC, CunninghamD, et al.Systematic review, including meta‐analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer2007;96:1183. CrossRef

161. LoehrerPJSr, FengY, CardenesH, et al.Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol2011;29:4105. CrossRef

162. CraneCH, VaradhacharyGR, YordyJS, et al.Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol2011;29:3037. CrossRef

163. TrutyMJ, ThomasRM, KatzMH, et al.Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg2012;215:41; discussion 2. CrossRef

164. HuguetF, AndreT, HammelP, et al.Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol2007;25:326. CrossRef

165. KrishnanS, RanaV, JanjanNA, et al.Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer2007;110:47. CrossRef

166. HuguetF, GirardN, GuercheCS, et al.Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol2009;27:2269. CrossRef

167. FarisJE, BlaszkowskyLS, McDermottS, et al.FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist2013;18:543. CrossRef

168. HammelP, HuguetF, Van LaethemJ‐L, et al.Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol2013;31:abstract LBA4003.

169. HeinemannV, BoeckS, HinkeA, et al.Meta‐analysis of randomized trials: evaluation of benefit from gemcitabine‐based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer2008;8:82. CrossRef

170. MooreMJ, GoldsteinD, HammJ, et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:1960. CrossRef

171. ColucciG, GiulianiF, GebbiaV, et al.Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer2002;94:902. CrossRef

172. HeinemannV, QuietzschD, GieselerF, et al.Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol2006;24:3946. CrossRef

173. ColucciG, LabiancaR, Di CostanzoF, et al.Randomized phase III trial of gemcitabine plus cisplatin compared with single‐agent gemcitabine as first‐line treatment of patients with advanced pancreatic cancer: the GIP‐1 study. J Clin Oncol2010;28:1645. CrossRef

174. LouvetC, LabiancaR, HammelP, et al.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol2005;23:3509. CrossRef

175. PoplinE, FengY, BerlinJ, et al.Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed‐dose rate infusion) compared with gemcitabine (30‐minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol2009;27:3778. CrossRef

176. KindlerHL, NiedzwieckiD, HollisD, et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol2010;28:3617. CrossRef

177. PhilipPA, BenedettiJ, CorlessCL, et al.Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group‐directed intergroup trial S0205. J Clin Oncol2010;28:3605. CrossRef

178. ConroyT, GavoilleC, SamalinE, et al.The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep2013;15:182. CrossRef

179. AssafE, Verlinde‐CarvalhoM, DelbaldoC, et al.5‐fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second‐line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology2011;80:301. CrossRef

180. BreysacherGKO, LemarignierC. Safety and clinical effectiveness of FOLFIRINOX in metastatic pancreas cancer after first‐line therapy. J Clin Oncol2010;28:Abstract 269.

181. Von HoffD, ErvinTJ, ArenaFP, et al.Randomized phase III study of weekly nab‐paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol2012;30:abstract LBA148.

182. KimR, MahipalA, ChoiM, et al.Biomarkers for pancreatic cancer: is it ready for primetime?JOP2013;14:309.

183. RamanathanRK, AbbruzzeseJ, DragovichT, et al.A randomized phase II study of PX‐12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine‐containing combination. Cancer Chemother Pharmacol2011;67:503. CrossRef

184. UenoH, IokaT, IkedaM, et al.Randomized phase III study of gemcitabine plus S‐1, S‐1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol2013;31:1640. CrossRef

185. PelzerU, SchwanerI, StielerJ, et al.Best supportive care (BSC) versus oxaliplatin, folinic acid and 5‐fluorouracil (OFF) plus BSC in patients for second‐line advanced pancreatic cancer: a phase III‐study from the German CONKO‐study group. Eur J Cancer2011;47:1676. CrossRef

186. XiongHQ, VaradhacharyGR, BlaisJC, et al.Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer. Cancer2008;113:2046. CrossRef

187. KulkeMH, BlaszkowskyLS, RyanDP, et al.Capecitabine plus erlotinib in gemcitabine‐refractory advanced pancreatic cancer. J Clin Oncol2007;25:4787. CrossRef

188. IsayamaH, NakaiY, YamamotoK, et al.Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Oncology2011;80:97. CrossRef

189. YooC, HwangJY, KimJE, et al.A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second‐line therapy in patients with gemcitabine‐refractory advanced pancreatic cancer. Br J Cancer2009;101:1658. CrossRef

190. YiSY, ParkYS, KimHS, et al.Irinotecan monotherapy as second‐line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol2009;63:1141. CrossRef

191. CollissonEA, SadanandamA, OlsonP, et al.Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med2011;17:500. CrossRef

192. HarshaHC, KandasamyK, RanganathanP, et al.A compendium of potential biomarkers of pancreatic cancer. PLoS Med2009;6:e1000046. CrossRef

193. GiovannettiE, Del TaccaM, MeyV, et al.Transcription analysis of human equilibrative nucleoside transporter‐1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res2006;66:3928. CrossRef

194. FarrellJJ, ElsalehH, GarciaM, et al.Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology2009;136:187. CrossRef

195. KimR, TanA, LaiKK, et al.Prognostic roles of human equilibrative transporter 1 (hENT‐1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer2011;117:3126. CrossRef

196. NeoptolemosJP. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5‐FU on the ESPAC trials. J Clin Oncol2013;31:abstract 4006.

197. DezielDJ, WilhelmiB, StarenED, et al.Surgical palliation for ductal adenocarcinoma of the pancreas. Am Surg1996;62:582.

198. LillemoeKD, CameronJL, HardacreJM, et al.Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg1999;230:322; discussion 8. CrossRef

199. van HeekNT, van GeenenRC, BuschOR, et al.Palliative treatment in “peri”‐pancreatic carcinoma: stenting or surgical therapy?Acta Gastroenterol Belg2002;65:171.

200. Morris‐StiffG, HassnA, YoungWT. Self‐expanding metal stents for duodenal obstruction in advanced pancreatic adenocarcinoma. HPB (Oxford)2008;10:134. CrossRef

201. RockeyPa. Cancer pain and symptom management: drug therapy. In: LowyAL(ed). Pancreatic Cancer. New York: Springer; 2008: 435. CrossRef

202. trials.gov C.2013. Available from: http://www.cancer.gov/clinicaltrials/search/view?cdrid=745198&version=HealthProfessional&protocolsearchid=8182450.

203. Dominguez‐MunozJE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol2011;26:12. CrossRef

204. WeiMY, GarlandCF, GorhamED, et al.and prevention of colorectal adenoma: a meta‐analysis. Cancer Epidemiol Biomarkers Prev2008;17:2958. CrossRef

205. GarlandCF, GorhamED, MohrSB, et al.Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol2007;103:708. CrossRef

206. GarlandCF, MohrSB, GorhamED, et al.Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med2006;31:512. CrossRef

207. GarlandCF, GarlandFC, GorhamED, et al.The role of vitamin D in cancer prevention. Am J Public Health2006;96:252. CrossRef

208. GrantWB. Relation between prediagnostic serum 25‐hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B2010;101:130. CrossRef

209. HariharanD, SaiedA, KocherHM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford)2008;10:58062.

210. KastrinosF, MukherjeeB, TayobN, et al.Risk of pancreatic cancer in families with Lynch syndrome. JAMA2009;302:1790. CrossRef

211. LowenfelsAB, MaisonneuveP, DiMagnoEP, et al.Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst1997;89:442. CrossRef

212. LowenfelsAB, MaisonneuveP, WhitcombDC, et al.Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA2001;286:169. CrossRef

213. van LierMG, WagnerA, Mathus‐VliegenEM, et al.High cancer risk in Peutz‐Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol2010;105:1258; author reply 65. CrossRef

214. WinterJM, MaitraA, YeoCJ. Genetics and pathology of pancreatic cancer. HPB (Oxford)2006;8:324. CrossRef

215. CunninghamD, ChauI, StockenDD, et al.Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol2009;27:5513. CrossRef

216. Van CutsemE, VervenneWL, BennounaJ, et al.Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol2009;27:2231. CrossRef

217. MaedaA, BokuN, FukutomiA, et al.Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S‐1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC‐01). Jpn J Clin Oncol2008;38:227. CrossRef